Lenvatinib + pembrolizumab delivers sustained efficacy in aRCC regardless of baseline bone metastases: Final analysis from CLEAR

Osimertinib + plat-pem shows consistent OS benefits in EGFRm advanced NSCLC irrespective of poor baseline prognostic factors: Exploratory OS analyses from FLAURA2

Alectinib prolongs OS and shows durable response in previously untreated advanced ALK+ NSCLC: Final OS analysis from the phase 3 ALEX study

Adjuvant abemaciclib + ET reduces risk of death in HR+, HER2-, high-risk early breast cancer: Primary OS results from the monarchE trial

Initial results from the PATHFINDER 2 study highlight efficacy of multi-cancer early detection testing